EUVIMEDEUVIMED entdecken
Open Access

Design of a potent interleukin-21 mimic for cancer immunotherapy

Jung-Ho Chun iD, Birkley S Lim iD, Suyasha Roy iD, Michael J Walsh iD, Gita C Abhiraman iD, Kevin Zhangxu iD, Tavus Atajanova, Or-Yam Revach iD, Elisa C Clark, Peng Li, Claire A Palin, Asheema Khanna und 32 weitere

Science Immunology · 2025

DOI: 10.1126/sciimmunol.adx1582 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Immunology, 2025. Verfasst von Jung-Ho Chun und 43 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Protein Design, University of Washington, Seattle, WA, USA. Hauptthemen laut MEDLINE: Interleukins, Immunotherapy, Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIAID NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Long-standing goals of cancer immunotherapy are to activate cytotoxic antitumor T cells across a range of affinities for tumor antigens while suppressing regulatory T cells. Computational protein design has enabled the precise tailoring of proteins to meet specific needs. Here, we report a de novo designed IL-21 mimic, 21h10, with high stability and signaling potency in humans and mice. In murine and ex vivo human organotypic tumor models, 21h10 showed robust antitumor activity, with more prolonged signaling and stronger antitumor activity than native IL-21. 21h10 induced pancreatitis that could be mitigated by TNF blockade without compromising antitumor efficacy. Although antidrug antibodies to 21h10 formed, they were not neutralizing. 21h10 induced highly cytotoxic T cells with a range of affinities, robustly expanding intratumoral low-affinity cytotoxic T cells and driving high expression of IFN-γ and granzyme B compared with native IL-21, while increasing the frequency of IFN-γ + T helper 1 cells and reducing regulatory T cells. The full human-mouse cross-reactivity, high stability and potency, and low-affinity antitumor responses support the translational potential of 21h10.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InterleukinsImmunotherapyNeoplasmsInterleukin-21AnimalsHumansMiceMice, Inbred C57BLFemaleCell Line, TumorT-Lymphocytes, Cytotoxic

Substanzen

Interleukin-21Interleukins

Autor:innen und Institutionen

  • Institute for Protein Design, University of Washington, Seattle, WA, USA.
  • Department of Biochemistry, University of Washington School of Medicine, Seattle, WA, USA.
  • Graduate Program in Biological Physics, Structure and Design, University of Washington, Seattle, WA, USA.
  • Department of Medicine, Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA.
  • Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

ORCID-Profile: Jung-Ho Chun, Birkley S Lim, Suyasha Roy, Michael J Walsh, Gita C Abhiraman, Kevin Zhangxu, Or-Yam Revach, Samantha Tower, Rakeeb Kureshi, Megan T Hoffman, Tatyana Sharova, Aleigha Lawless, Genevieve M Boland, Tina Nguyen, Frank Peprah, Julissa G Tello, Samantha Y Liu, Chan Johng Kim, Hojeong Shin, Alfredo Quijano-Rubio, Kevin M Jude, Stacey Gerben, Analisa Murray, Piper Heine, Umut Y Ulge, Lauren Carter, Neil P King, Daniel-Adriano Silva, Hao Yuan Kueh, Surojit Sarkar, Russell W Jenkins, Warren J Leonard, Michael Dougan, Stephanie K Dougan, David Baker

Förderung

  • NIGMS NIH HHS
  • NIAID NIH HHS
  • NCI NIH HHS
  • NIBIB NIH HHS
  • NIA NIH HHS
  • Howard Hughes Medical Institute

Zitieren

APA

Chun, J. H., Lim, B. S., Roy, S., Walsh, M. J., Abhiraman, G. C., Zhangxu, K., Atajanova, T., Revach, O. Y., Clark, E. C., Li, P., Palin, C. A., Khanna, A., Tower, S., Kureshi, R., Hoffman, M. T., Sharova, T., Lawless, A., Cohen, S., Boland, G. M., …, & Baker, D. (2025). Design of a potent interleukin-21 mimic for cancer immunotherapy. Science Immunology. https://doi.org/10.1126/sciimmunol.adx1582

Vancouver

Chun JH, Lim BS, Roy S, Walsh MJ, Abhiraman GC, Zhangxu K, et al. Design of a potent interleukin-21 mimic for cancer immunotherapy. Science Immunology. 2025. doi:10.1126/sciimmunol.adx1582

BibTeX
@article{Chun2025,
  author = {Chun, Jung-Ho and Lim, Birkley S and Roy, Suyasha and Walsh, Michael J and Abhiraman, Gita C and Zhangxu, Kevin and Atajanova, Tavus and Revach, Or-Yam and Clark, Elisa C and Li, Peng and Palin, Claire A and Khanna, Asheema and Tower, Samantha and Kureshi, Rakeeb and Hoffman, Megan T and Sharova, Tatyana and Lawless, Aleigha and Cohen, Sonia and Boland, Genevieve M and Nguyen, Tina and Peprah, Frank and Tello, Julissa G and Liu, Samantha Y and Kim, Chan Johng and Shin, Hojeong and Quijano-Rubio, Alfredo and Jude, Kevin M and Gerben, Stacey and Murray, Analisa and Heine, Piper and DeWitt, Michelle and Ulge, Umut Y and Carter, Lauren and King, Neil P and Silva, Daniel-Adriano and Kueh, Hao Yuan and Kalia, Vandana and Sarkar, Surojit and Jenkins, Russell W and Garcia, K Christopher and Leonard, Warren J and Dougan, Michael and Dougan, Stephanie K and Baker, David},
  title = {Design of a potent interleukin-21 mimic for cancer immunotherapy},
  journal = {Science Immunology},
  year = {2025},
  doi = {10.1126/sciimmunol.adx1582}
}
Kostenlos starten →